Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 06/07/2011) - A four-drug chemotherapy regimen has produced the longest improvement in survival ever seen in a phase III clinical trial of patients with metastatic pancreatic cancer, one of the deadliest types of cancer.
Five Years of Tamoxifen Continues to Benefit Women 15 Years after Treatment
(Posted: 06/03/2011) - In a large randomized clinical trial, women with early-stage breast cancer who received 5 years of adjuvant treatment with tamoxifen had better outcomes up to 15 years after the start of treatment than those who received 2 years of tamoxifen therapy.
Menopausal Estrogen Therapy Benefits and Risks Vary by Age, WHI Analysis Suggests
(Posted: 05/20/2011) - Long-term follow-up data from the Women’s Health Initiative (WHI) provide important new information about the potential risks and benefits of hormone therapy to treat symptoms or conditions related to menopause, including its effect on breast cancer risk, according to results published April 5, 2011, in the Journal of the American Medical Association.
Adding Radiation to Chemotherapy May Improve Outcomes in Early-Stage Hodgkin Lymphoma
(Posted: 05/12/2011) - Adding radiation therapy to chemotherapy may improve outcomes in patients with early-stage Hodgkin lymphoma, according to a paper published in the Cochrane Database of Systematic Reviews in February 2011, but the long-term effects of this regimen are not known.
Trastuzumab after Chemotherapy Is Effective in HER2-Positive Breast Cancer
(Posted: 05/06/2011) - Treatment with trastuzumab for 1 year following standard chemotherapy improved disease-free survival in women with HER2-positive early breast cancer, according to 4-year follow-up results of the Herceptin Adjuvant (HERA) trial reported February 25, 2011, in Lancet Oncology.